March 15, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie reports $74.4 million net loss in 2015
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a GAAP net loss of $74.4 million, or $2.88 per share, in 2015, according to a company press release.
In 2014, the GAAP net loss was $48.1 million, or $2 per share.
A GAAP net loss of $20.4 million, or $0.76 per share, was reported in the fourth quarter compared with $16.5 million, or $0.69 per share, in the same quarter of 2014. The increase was attributed to $20 million in operating expenses, which included $12.3 million in research and development expenses and $7.6 million in general and administrative expenses.
High operating expenses in the fourth quarter were attributed to increased activities related to the phase 3 programs for Rhopressa and Roclatan.